TY - T1的血液嗜酸性粒细胞不预测haled budesonide response in bronchiectasis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02210-2020 VL - 56 IS - 3 SP - 2002210 AU - Aliberti, Stefano AU - Sotgiu, Giovanni AU - Martinez Garcia, Miguel-Angel Y1 - 2020/09/01 UR - //www.qdcxjkg.com/content/56/3/2002210.abstract N2 - We would like to thank B. Lipworth and co-workers for their feedback on our study, which showed that 6-month treatment with inhaled fluticasone proprionate (FP) significantly improved quality of life in bronchiectasis patients with neither asthma nor COPD, and with blood eosinophil counts either ≥3% or≥150 cells·μL−1 [1, 2]. We agree with B. Lipworth and co-workers on the higher dose-dependent suppression of blood eosinophils due to the systemic absorption of FP. We re-analysed previously published data on bronchiectasis patients treated with budesonide, which has less systemic potency than FP [3].Blood eosinophils do not predict inhaled budesonide response in bronchiectasis https://bit.ly/2Yr1b11 ER -